The Liver and Kidney in Critically Ill Patients

Andrew J. Slack    Julia Wendon
The Institute of Liver Studies, KCH, King’s College London, King’s College Hospital, London, UK

Key Words
Hepatorenal syndrome · Acute kidney injury · Renal blood flow · Cirrhotic cardiomyopathy

Abstract
Both liver and kidney dysfunction are associated with adverse outcomes in critical illness. Advanced liver disease can be complicated by the hepatorenal syndrome (HRS) with liver transplantation offering the best long-term outcome. However, until recently, HRS was associated with such a poor prognosis that this group of patients rarely survived long enough for transplantation to be considered. The use of vasopressin analogues and albumin infusions has improved the management of HRS and outcomes in terms of renal recovery and survival.

Introduction
Preservation of organ function is the keystone in the survival of critically ill patients on intensive care. It has been well reported that coexisting and indeed independent liver and renal dysfunction impact significantly on hospital and intensive care mortality [1]. For over 100 years the association between liver and kidney disease has been well documented. In 1877, the clinical phenomenon of oliguria, ascites and normal kidney histology was noted by Frerichs, a German pathologist. He went on to also describe the pathological changes seen in cirrhosis of the liver [2, 3]. The term hepatorenal syndrome (HRS) was first used in 1939 to describe kidney dysfunction following biliary surgery and liver trauma. HRS is a unique form of renal dysfunction that complicates advanced liver disease, acute hepatic failure or portal hypertension. The key pathological features are the development of cirrhotic cardiomyopathy and vasoactive mediator-induced circulatory dysfunction or ‘vascular failure’. HRS is a diagnosis of exclusion with other common causes of acute renal failure (ARF), including pre-renal, renal and post-renal causes also seen frequently in advanced liver disease. We will explore these and focus on HRS, which despite its functional nature, continues to be associated with a poor prognosis.

Epidemiology
UK-based population studies have estimated the annual incidence of ARF from 486 to 620 per million population, accounting for about 1% of hospital admissions and complicating >7% of hospital inpatient admissions [4, 5]. ARF is a common finding on the critical care unit with as many as 35% of patients admitted to ICU requiring renal replacement therapy (RRT) and, when present as part of multiple organ failure, mortality is >90% if four organs or more fail [6].

The commonest forms of ARF in cirrhotic patients with ascites are pre-renal failure and acute tubular necro-
sis (ATN) with prevalence rates of 42 and 38%, respectively. Post-renal failure occurs at a rate of 0.3%. HRS occurs in about 4% of patients admitted with decompen-
sated cirrhosis, the cumulative probability being 18% at 1 year, increasing to 39% at 5 years. In almost half the cas-
es of HRS, one or more precipitating factors may be iden-
tified, including bacterial infections (57%), gastrointesti-
nal haemorrhage (36%), and large volume paracentesis
(7%) [7]. Spontaneous bacterial peritonitis (SBP) is the
most frequent cause of renal failure in cirrhosis with ap-
proximately 30% of patients with SBP developing ARF
[8].

The epidemiology of studies on HRS in the future may
display the statistical phenomenon of stage migration,
because of alterations to the diagnostic criteria for HRS
in 2007. These future trials may demonstrate improved
outcomes and mortality figures, a reflection of stage mi-
gration, where patients fall into a different diagnostic
group associated with a reduced mortality [9].

Pathophysiology and Basic Science

The pathophysiology of HRS is complex, and yet it
seems certain that it is functional in nature and related to
three key areas – splanchnic, sympathomemetic and car-
diac factors – which will be discussed in more detail.

The evidence to support the functional nature of HRS
comes from a number of sources outlined below: (a) ini-
tially histological abnormalities are minimal and incon-
sistent; (b) tubular function and sodium absorption re-
 mains intact; (c) kidneys transplanted from patients with
HRS can resume normal function in the recipient, and (d)
renal function can return in patients with HRS who re-
ceive a liver transplant.

HRS and the associated intense renal vasoconstriction
is the result of two important physiological changes,
which have been shown to occur in advancing liver dis-
 ease, portal hypertension and acute liver failure. Firstly,
there is an increase in the level of endogenous vaso-
dilators and vasoconstrictors. Primarily, vasodilatation af-
tefts the splanchnic circulation and vasoconstriction the
renal circulation. Secondly, specific cardiac abnormali-
ties develop, leading to a cirrhotic cardiomyopathy, which
now appears to be crucial in the development of HRS.
This cirrhotic cardiomyopathy is unmasked during
stressful events like sepsis compounding the already es-
 tablished dysfunctional circulation, which has evolved as
 liver disease advances due to the release of the numerous
 vasoactive mediators.

Doppler studies have demonstrated the discrepancy of
vasodilatation in the splanchnic circulation and vaso-
constriction in muscle, kidney and cerebral circulations
[10]. Vasoactive mediators such as nitric oxide (NO), car-
bon monoxide, endothelin, prostacyclin and glucagon
have all been implicated in splanchnic vasodilatation [11,
12]. Evidence to support the role of such mediators has
come from studies assessing various antagonists. An en-
 dothelin antagonist, in particular, has been shown to im-
prove renal perfusion in patients with HRS, suggesting
that it may play a role in renal vasoconstriction. However,
due to conflicting results in these mediator antagonist
studies, further studies appear necessary to define the
individual role they play in HRS [13]. NO has been ex-
tensively studied and is believed to play a significant role
in the development of renal dysfunction. Animal studies
have used NO inhibitors in an induced acute liver failure
model in rats and demonstrated a reduction in serum cre-
tinine (SCr) [14].

Splanchnic

Splanchnic vasodilatation leads to a reduction in the
effective circulating blood volume [15], causing a fall in
the mean arterial pressure (MAP) and an increase, in an
attempt to compensate, in cardiac output. The fall in MAP
shifts the renal blood flow (RBF) autoregulation curve to
the right rendering it pressure dependant. The normal
physiologically range for renal autoregulation is a MAP of
70–75 mm Hg. The reduction in RBF leads to activation
of systemic endogenous vasoconstrictor systems, the sy-
mpathetic nervous system, the renin-angiotensin systems
and the non-osmotic release of vasopressin. Consequent-
ly, there is avid renal sodium retention resulting in ascites,
renal water conservation resulting in hyponatraemia and
severe renal vasoconstriction leading to HRS.

Sympathomemetic

The sympathetic nervous system is known to have
heightened activity in cirrhotic patients [16]. In a rat
model, the liver has been shown to be involved in the
regulation of sodium and water excretion by the kidney.
The involvement of the liver in the regulation of urine
production has been called the ‘hepatorenal reflex’ [17].
The hepatorenal reflex is thought to be initiated by cir-
rhosis-induced hepatic portal circulatory changes; both
increased portal venous pressure (PVP) and reduced por-
tal venous blood flow (PVBF). It has been difficult to se-
parate these two possible factors as most studies have in-
creased the PVP by occluding the portal vein thus reduc-
ing the PVBF.
A rat model where a portocaval shunt was formed to perform a controlled reduction in the intrahepatic blood flow was studied and demonstrated a decrease in sodium and water excretion. It was also shown that the administration of an adenosine antagonist reversed the antinatriuretic effect of the reduced PVBF. Adenosine accumulation in the liver increases hepatic artery blood flow and is thought to stimulate a large collection of nerves in the space of Mall. Adenosine may be acting as a neuromediator stimulating these afferent hepatic nerves leading to an increase in sympathetic activation to renal vessels.

It has been suggested that the liver possesses both sensory and homeostatic functions helping to regulate intravascular fluid via the hepatorenal reflex. There are, however, inconsistent findings in human studies regarding the hepatorenal reflex. The hepatorenal reflex does appear to be a pathophysiological response to maintain the effective circulating volume in patients with cirrhosis and reduced portal vein blood flow [18].

Cardiac

In advanced liver disease, sustained cardiac performance to maintain the hyperdynamic circulation ensuring a continued effective circulating blood volume and RBF appears vital to avoid HRS. However, it is well recognized that there is a greater prevalence of cardiomyopathy in patients with end-stage liver disease than in the general population [19]. Cirrhotic patients, in particular, develop a number of cardiac-specific abnormalities leading to the condition cirrhotic cardiomyopathy. It has been demonstrated that left ventricular work indices such as stroke index, mean systolic ejection rate, left ventricular stroke work are greater than expected in cirrhotic patients at rest, but have attenuated responses to exercise [20]. Histologically, there is myocardial hypertrophy, interstitial and cellular oedema and signs of cellular injury. This leads to left ventricular free wall and, in particular, septal thickening. This is evident to a greater extent in patients with ascites compared to those without [21]. The degree of diastolic dysfunction increases with increasing wall thickness and leads to prolonged isovolumetric relaxation, greater ventricular pressure for the end-diastolic volume. Cardiac failure can then develop acutely with any rapid increases in filling pressure and may explain why patients decompensate after transjugular intrahepatic portosystemic shunts (TIPSS) and transplantation. Other cardiac-specific changes in cirrhotic cardiomyopathy include electrophysiological repolarization changes, enlargement of cardiac chambers, and a reduced response of the heart to direct β-stimulation (β-incompetence).

All these changes occur in the absence of overt congestive failure [22], but render the cirrhotic patient precarious and vulnerable to stressful stimuli like sepsis.

 Decompensated liver disease and the development of ascites occur due to the compensatory effects of the activation of vasoconstrictor and antinatriuretic factors attempting to maintain the effective circulating volume. The increasing volume of ascites leads to an increase in intra-abdominal pressure (IAP), which affects the circulation by reducing venous return.

Diagnosis

The diagnosis of ARF and assessment of glomerular filtration rate (GFR) relies on the measurement of SCr. There remain diagnostic problems with SCr, and these are particularly evident in liver disease. Bilirubin is known to interfere with assays, with hyperbilirubinaemia masking increases in SCr. The degree of error can be up to 57%, but modern autoanalyzers and the use of the end-point Jaffe method have overcome such interference. However, caution should be employed when interpreting SCr results in the context of hyperbilirubinaemia. The measurement of SCr is also affected by two particularly important factors, muscle mass and liver synthetic function. The production of creatinine is reduced by 50% and this in combination with protein malnutrition and muscle wasting result in a significantly lower baseline range for creatinine in advanced liver disease (35–75 μmol/l).

Cirrhotic patients for a given change in GFR tend to have smaller and delayed changes in SCr, underestimating and impairing the recognition of change in GFR [23]. Novel biomarkers for the measurement of GFR are being explored, but a more reliable marker is yet to be found. The best marker of GFR continues to be the SCr, if interpreted with a full understanding of its pitfalls, and it is cheap and widely available.

ARF is a complex disorder, with over 30 definitions, and attempts have been made in recent years to create a uniform standard for diagnosis and classification. Members representing key societies in critical care and nephrology set up the Acute Kidney Injury Network (AKIN) to review the RIFLE criteria used for defining and classifying ARF. Acute kidney injury is the new term used to represent the entire spectrum of ARF, recognizing that an acute decline in kidney function is often secondary to an injury that causes functional or structural changes in the kidneys.
The AKIN group decided to revise RIFLE criteria, specifically the ‘Risk’ category to take into account evidence demonstrating that adverse outcomes are associated with small rises in SCr occurring in 24–48 h, reflecting an acute and significant change in GFR [24]. Patients with a SCr rise >26.4 μmol/l were included in stage 1 of the AKIN staging system rather than use >25% increase from baseline SCr as was the case for RIFLE (table 1). It was assumed this would improve sensitivity and predictability of the definition and classification of AKI. However, a recent study has demonstrated this amounts to only 1%, which is a favourable outcome, because RIFLE has already been validated in over 200,000 patients and is widely used [25]. Therefore, RIFLE and AKI staging are essentially the same with the category ‘Risk’ being the equivalent to stage 1, ‘Injury’ stage 2 and ‘Failure’ stage 3. ‘Loss’ and ‘End-stage’ have been removed from AKI, but remain as outcomes. Patients receiving RRT are automatically included in stage 3. Urine output is used as one of the diagnostic criteria, because despite its many shortcomings, it is recognized as a useful measure in critically ill patients as it can often herald the onset of AKI before changes in SCr are identified.

The definition and criteria for staging AKI are useful as it alerts us to the significant impact AKI stage has on clinical outcomes (fig. 1). With further validation it could be possible to incorporate one of these AKI staging systems into the criteria for defining HRS, unless a better biomarker of AKI can be found.

Kaplan-Meier curves for survival using RIFLE criteria for AKI in cirrhotic patients who are critically ill have demonstrated this staging system to be a good predictor of hospital survival [26].

Table 1. Classification/staging system for acute kidney injury

<table>
<thead>
<tr>
<th>Stage</th>
<th>Increase in serum creatinine</th>
<th>Urine output</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>&gt;26.4 μmol/l or &gt;150–200% from baseline (1.5- to 2-fold)</td>
<td>&lt;0.5 ml/kg/h</td>
</tr>
<tr>
<td>2</td>
<td>&gt;200–300% from baseline (&gt;2- to 3-fold)</td>
<td>&lt;0.5 ml/kg/h</td>
</tr>
<tr>
<td>3</td>
<td>&gt;300% from baseline (&gt;3-fold) or SCr &gt;354 μmol/l with acute increase of 44 μmol/l or receiving RRT</td>
<td>&lt;0.3 ml/kg/h</td>
</tr>
</tbody>
</table>

Fig. 1. Cumulative survival rate for 134 critically ill cirrhotic patients based on their RIFLE classification (a) and SOFA (b) on day 1 of ICU admission (permission granted by Y.-C. Chen, MD, Chang Gung Memorial Hospital, Taipei, to use this figure).
The diagnosis of HRS is one of exclusion, so investigations should be performed to rule out other common causes of AKI. The characteristic urinary excretory patterns observed in HRS are indistinguishable from pre-renal failure or myoglobinuric ATN, where tubular function and the capacity to concentrate remain intact. The measurement of urinary sodium, osmolality or creatinine has little role to play in directing management in clinical practice.

HRS can be diagnosed if various criteria are met in accordance with those agreed by the International Ascites Club. This club has met twice in the last 15 years, and on the most recent occasion in 2006 new criteria were agreed. The changes to the criteria were based on new concepts which had emerged in the intervening years. The key concepts came from Doppler studies evaluating the various vascular beds and cardiac studies demonstrating cirrhosis-induced cardiomyopathy were also important. There was a recognition that there had been an improvement in survival associated with the use of vasoconstrictor therapy and TIPSS for bacterial infections that caused HRS (table 2).

### HRS Classification and Its Problems

HRS is defined on the basis of a SCr >130 μmol/l without reference to gender or ethnicity, and at this level a significant number of patients will not fulfil the diagnostic criteria based on creatinine. In advanced liver disease the associated lower baseline SCr observed results in a large proportion of patients losing >50% of function before the diagnosis of HRS could be considered.

HRS is further divided into two subtypes, HRS type 1 and type 2, which are clinically quite separate and the differences are illustrated in table 3.

<table>
<thead>
<tr>
<th>Is HRS-1 a Form of AKI?</th>
</tr>
</thead>
<tbody>
<tr>
<td>HRS-1 is a potentially reversible deterioration of systemic circulatory function or ‘vascular failure’, involving a combination of factors, but primarily involving splanchnic vasodilatation and renal vasoconstriction, often triggered by a precipitating event. The acute ischaemic injury probably falls somewhere along the spectrum between classical pre-renal failure at one end and the histological definition of ATN at the other. Indeed, a histological study in 5 patients with HRS type 1 assessed kidney biopsy specimens by light and electron microscopy. It demonstrated necrosis of the proximal tubules characterized by swelling, disorganization of the cristae and the appearance of dark bodies in the mitochondria, coalescence, fragmentation or displacement of the microvilli, loss of plasma membranes, rupture of the basement membranes, and separation of the cells from the basement membranes. Rupture of tubular basement membranes (tubulorrhexis) and mitochondrial dark bodies suggested an ATN due to ischaemia or induced by vasoconstrictor substances [28].</td>
</tr>
</tbody>
</table>

### Table 2. Comparison of the criteria for the diagnosis of HRS agreed at the International Ascites Club meetings in 1994 and 2007

<table>
<thead>
<tr>
<th>1994</th>
<th>2007</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Major criteria</strong></td>
<td></td>
</tr>
<tr>
<td>Chronic or active liver disease with advanced hepatic failure and portal hypertension</td>
<td>Cirrhosis with ascites</td>
</tr>
<tr>
<td>Low GFR (SCr &gt;1.5 mg/dl)</td>
<td>SCr &gt;1.5 mg/dl or &gt;130 μmol/l</td>
</tr>
<tr>
<td>Absence of shock, ongoing infection, and current or recent treatment with nephrotoxic drugs. Absence of gastrointestinal fluid losses (repeated vomiting or intense diarrhoea) or renal fluid losses (wt &gt;500 g/day in patients with ascites without peripheral oedema or 1,000 g/day in patients with peripheral oedema</td>
<td>Absence of shock</td>
</tr>
<tr>
<td>No sustained improvement in renal function (decrease in SCr to 1.5 mg/dl or less, or increase in creatinine clearance to 40 ml/min or more) following diuretic withdrawal and expansion of plasma volume with 1.5 l of isotonic saline</td>
<td>No improvement in SCr (decrease to a level of &lt;1.5 mg/dl) after 2 days with diuretic withdrawal and volume expansion with albumin. The recommended dose of albumin is 1 g/kg of body weight per day up to a maximum of 100 g/day</td>
</tr>
<tr>
<td>Proteinuria &lt;500 mg/day and no ultrasound evidence of obstructive uropathy or parenchymal disease</td>
<td>Absence of parenchymal kidney disease as indicated by proteinuria &lt;500 mg/day, microhaematuria (&lt;50 RBC/high-power field) and/or abnormal renal ultrasound</td>
</tr>
<tr>
<td><strong>Minor criteria</strong></td>
<td></td>
</tr>
<tr>
<td>Urine volume &lt;500 ml/day</td>
<td>No current or recent treatment with nephrotoxic drugs</td>
</tr>
<tr>
<td>Urine sodium &lt;10 mmol/l</td>
<td></td>
</tr>
<tr>
<td>Urine osmolality greater than plasma osmolality</td>
<td></td>
</tr>
<tr>
<td>Urine red blood cell &lt;50/HPF</td>
<td></td>
</tr>
<tr>
<td>Serum sodium concentration &lt;130 mmol/l</td>
<td></td>
</tr>
</tbody>
</table>
The improved understanding of ATN has recognized that there is more than just an upset in haemodynamic autoregulatory mechanisms, which normally preserves the intraglomerular pressure. The contributions of endothelial, leukocyte activation and the release of cytokines causing an oxidative stress at a cellular level are important in the development of kidney injury. The models of AKI in sepsis and HRS-1 seem to be very similar, and the pathological mechanism perhaps explains why improving renal perfusion alone does not always result in improved kidney function. Future therapies aimed at improving RBF, enhancing natriuresis, and dampening down inflammation, free radicals and oxidative stresses are all likely to be important.

HRS-1, unlike HRS-2, is an ‘acute’ pathology defined as a doubling of SCr >225 μmol/l within 2 weeks from the initial defining SCr >130 μmol/l. This is far removed from the latest acute kidney injury staging system, where stage 1 is defined as a 150–200% increase from baseline. Stage 1 AKI for patients diagnosed with HRS would equate to a rise in SCr >195–260 μmol/l within 48 hours. The rate of change between the two classifications varies enormously, 48 hours compared to 2 weeks. Many patients with acute liver disease have a progressive condition evolving over days or weeks exposing them to the increased risk of HRS, which can develop at any point in time during their illness. This, though, should not preclude these patients from being assessed for the insult of acute kidney injury using the AKI staging criteria.

Is HRS-2 a Form of Chronic Kidney Disease (CKD)?

HRS-2 is perhaps a form of chronic ischaemic nephropathy similar to that encountered in patients with chronic heart failure, which is exacerbated by precipitating events. Patients with liver disease have the additional burden of large volume, often refractory, ascites and a raised IAP. The effect of diuretics and a raised IAP have important effects on kidney haemodynamics, which are significant and may account for the slow deterioration in kidney function.

HRS-2 appears to be a ‘chronic’ form of kidney disease, which is associated with refractory ascites. Patients with the HRS-2 condition perhaps should be classified using CKD staging criteria, which were developed by the Kidney Disease Outcome Quality Initiative (K/DOQI) workgroup to help manage and stage CKD. It relies on using estimated GFR (eGFR) calculated using the modified diet in renal disease (MDRD) calculation. There are different versions of the MDRD calculated eGFR; the extended version incorporates albumin and urea. The standard MDRD eGFR has a sensitivity of 65–74% in predicting GFR in liver disease, and is now considered by many to be the ‘gold standard’ [27].

If HRS-2 is considered a form of CKD, then the scenario of a 45-year-old male with a SCr between 110 and 225, with an albumin of 16 and an urea of 8 would equate to CKD stage 3–4, if calculated using the MDRD equa-
Acute kidney injury (AKI) is a transient form of renal failure. The patient in this example with stage 3–4 CKD will have experienced a significant loss in kidney function, and any opportunity to assess the rate of progression and perform a thorough investigation to exclude important underlying parenchymal diseases or exacerbating factors will have been missed (table 4).

Problems with the HRS Criteria

There are problems with the current definition of HRS and importantly how the subgroups of HRS-1 and HRS-2 are defined and identified. The initial defining criteria of a SCr >130 μmol/l is not reflective of the lower baseline SCr concentration seen in these patients, and it is not adjusted for gender or ethnicity. HRS should perhaps be divided into acute and chronic HRS. Acute HRS and AKI staging could be employed based on changes in the individual baseline SCr measurement and urine output when available. Chronic HRS could be defined using CKD staging criteria where patients have eGFR calculated using one of the MDRD equations and then management directed in line with current CKD guidelines. The nephrology community has embraced these staging systems for AKI and CKD, acknowledging their pitfalls, but importantly recognizes that they can alert clinicians earlier to patients with renal disease. This is important, because there is an abundance of evidence demonstrating that even a small degree of kidney injury is associated with an increased mortality and that CKD is significantly associated with an increase in cardiovascular disease.

Prevention

Simple measures may prevent AKI, including the temporary omission of nephrotoxic drugs together with appropriate adjustment of drug doses for the eGFR. Diuretic dosing is especially important in patients with ascites or cardiac failure. Twenty percent of patients with ascites develop moderate renal impairment, related to excessive diuresis and intravascular depletion, which is often rapidly reversible following diuretic withdrawal.

Radiological investigation requiring contrast should be performed once measures to prevent contrast-induced nephropathy have been implemented. There is much debate about the pathogenesis and management of this condition. However, both volume loading with isotonic bicarbonate and the use of the antioxidant agent N-acetyl-cysteine have been shown to reduce the occurrence of contrast-induced nephropathy in patients at risk [29, 30].

The prevention of HRS is limited to targeting the precipitating events and reducing the incidence with which they occur. Orthotopic liver transplantation (OLT) and TIPSS may be useful interventions, but patient selection needs collective careful consideration.

SBP can cause hepatic encephalopathy and HRS-1 and is associated with 30% hospital mortality despite infection resolution. Volume expansion with albumin (1.5 g/kg day 1, 1 g/kg day 3) has been shown to significantly reduce the incidence of HRS and hospital mortality associated with SBP. The albumin effect is related to improvements in systemic haemodynamics, indicated by plasma renin aldosterone (PRA) suppression. The patients who benefitted in this study were those with a serum bilirubin >68 mmol/l (4 mg/dl) and a SCr >88.4 mmol/l (1 mg/dl) [31]. Trials need to be conducted so that the optimum dosage to be used can be defined more precisely.

Studies into antibiotic prophylaxis for recurrent SBP have demonstrated it to be highly effective and cost-effective at reducing recurrent events. However, the use of antibiotics as primary prophylaxis with norfloxacin is not so clear. A recent study suggested that primary prophylaxis reduces the incidence of SBP, delaying the development of HRS, and improving survival. It would appear though, that further work is still required to establish the clinical and cost effectiveness of primary prophylaxis in this group of patients. This is even more apparent given the associated increased incidence of Gram-positive organisms, which has been shown in those treated with norfloxacin [32].

Many studies have reviewed both the medical and endoscopic therapies that can prevent variceal bleeding. There is no effective therapy for the prevention of varices, but β-blockade can prevent the enlargement of varices and so reduce the risk of bleeding. They have been shown to clearly reduce the risk of variceal bleeding in moderate to large varices and some evidence, although weak, suggests endoscopic banding is superior to medical therapy [33]. Often the episode of AKI associated with variceal bleeding is related to the period of volume depletion and hypotension.

Management Strategy

AKI in advanced liver disease whatever the cause should be focused on the early optimization of renal perfusion with the goal of saving nephrons. Strategies be-
Beyond resuscitation used for the treatment of HRS have included the use of vasopressors and albumin, TIPSS and OLT.

### Haemodynamic Resuscitation

The Surviving Sepsis Campaign initial resuscitation recommendations, which were developed to help direct therapy in patients with sepsis or sepsis-induced organ dysfunction (shock), provide useful initial targets for patients with AKI, but are not validated for patients with liver disease [34]. There are problems associated with the measurement of central venous pressures and ScvO\(_2\) in patients with liver disease. Central venous pressure is elevated by large volume ascites and raised intra-abdominal pressure. ScvO\(_2\) is often significant raised in patients with advanced liver disease reflecting the hyperdynamic circulation.

The Surviving Sepsis Campaign recommends commencing resuscitation in any patient who is hypotensive, MAP <70 mm Hg, or has an elevated serum lactate >4 mmol/l, and to give due consideration of management being transferred to a critical care environment. The lactate threshold of 4 mmol/l in a cirrhotic patient may of course be difficult to interpret, but a rising trend would still suggest significant circulatory disarray.

In patients with advanced liver disease, the issues that cloud the conventional measures of central blood volume and tissue perfusion often necessitate the earlier institution of invasive haemodynamic monitoring. This is especially advisable when there has been failure to achieve a MAP >65 mm Hg or urine output 0.5 ml/kg/min with fluid resuscitation, and the decision to commence inotropic or vasopressor support has been taken. When sepsis is suspected, cultures should be taken from different sites and antibiotics commenced within an hour of diagnosis.

Cirrhotic patients can often present unwell with tense ascites, and this causes intra-abdominal hypertension (IAH). IAH that exceeds 25 mm Hg can result in significant compromise to cardiac, respiratory and renal function. Large volume therapeutic paracentesis can help to reduce IAH often immediately improving respiratory mechanics. Support with albumin and vasopressors is essential to prevent exacerbation of the established circulatory disturbances. Small volume paracentesis should sometimes be considered as this may avoid the dramatic effects on the central haemodynamics incurred with higher volume paracentesis.

### Orthotopic Liver Transplantation

The modified end-stage liver disease (MELD) scoring system was developed to predict survival for patients undergoing TIPSS. This was then utilized to predict the risk of death within 3 months of diagnosis of advanced liver disease in order to prioritize these patients for cadaveric liver transplant. In February 2002, the United States adopted the MELD score to rank patients accordingly on transplant waiting lists. The MELD score uses a mathematical formula based on Scr, bilirubin, and INR. MELD scores can range from 6 to 40 (MELD scores >40 are all grouped together and receive a score of 40). MELD = 3.8 [In serum bilirubin (mg/dl)] + 11.2 [In INR] + 9.6 [In Scr (mg/dl)] + 6.4. MELD has helped those with HRS and a high Scr to gain a higher priority. However, it has been demonstrated that due to the problems with variations in SCR measurement due to high levels of bilirubin, muscle mass, gender and age there are significant variations in MELD scores. Although this may not affect survival prediction score, it can affect ranking on transplant waiting lists [35].

Many patients with HRS-1 are unsuitable for transplantation, because of significant associated organ dysfunction or indeed they die before transplantation is possible. HRS at the time of transplantation is associated with a negative effect on outcome in terms of survival, renal recovery, need for long-term RRT, cost effectiveness and quality of life [36]. Ongoing debate and research is trying to elucidate which of these patients should receive a combined kidney and liver transplant or liver transplant alone.

### Vasopressors, Albumin and TIPSS

Most studies in HRS-1 have been non-randomized and concentrated on the use of vasopressors (midodrine, terlipressin and noradrenaline), octreotide and albumin infusion. Midodrine and noradrenaline are \(\alpha\)-agonists, which improve systemic blood pressure by increasing systemic vascular resistance. Octreotide antagonizes the splanchnic vasodilators. Terlipressin is a V1 vasopressin agonist, which increases both systemic and splanchnic vascular resistance increasing effective circulating blood volume.

### HRS

The vasopressor studies to date have used mostly bolused terlipressin or continuously infused vasopressin and demonstrated recovery rates for HRS-1 of around 59%. Interestingly, terlipressin in conjunction with albumin infusions have been shown to be superior than terlipressin alone with respect to renal recovery. The combi-
nation of midodrine and octreotide has also been studied, and resulted in a 49% recovery rate [37].

One prospective, randomized, double-blind, placebo-controlled clinical trial of terlipressin has been performed. Patients with type 1 HRS were randomized to terlipressin (1 mg every 6 h) or placebo, with albumin in both groups. Terlipressin was superior to placebo with reversal rates for HRS-1 of 34 and 13%, respectively. Transplantation-free survival was similar between study groups, but HRS reversal significantly improved survival at day 180 [38].

The role of TIPSS in HRS-1 has been studied on only a few occasions and restrictive patient selection criteria make it difficult to extrapolate these findings into daily clinical practice. The TIPSS procedure reduces the portal pressure and sympathetic drive, which has been shown to affect renal haemodynamics. Patients with advanced liver disease must be carefully selected for the TIPSS procedure, because the reduction in portal blood flow to the liver can precipitate decompensation of liver function and precipitate encephalopathy.

Wong et al. [39] evaluated the additional improvement of renal function following TIPSS in patients with HRS-1. They selected patients who had improved renal function with medical therapy and enrolled patients for TIPSS therapy, unless they had contraindications for TIPSS insertion. These included an international normalized ratio $\geq 2$, a serum bilirubin $>85$ μmol/l (5 mg/dl), a Child-Turcotte-Pugh score of $\geq 12$, or thrombosed portal vein and active infection within the previous 2 weeks. They showed that patients treated with TIPSS had significant further sustained improvement of renal function and elimination of ascites [40].

**HRS-2**

HRS-2 is associated with refractory ascites and progressive renal impairment. Refractory ascites is managed either by paracentesis or TIPSS and only a few trials have been performed comparing these two treatment options. TIPSS is superior to paracentesis in the prevention of refractory ascites. The incidence of gastrointestinal bleeding, infection and AKI are similar for both treatment groups. TIPSS is thought associated with an increased incidence of encephalopathy.

The use of vasoressor therapy with albumin and TIPSS alone has been studied for the treatment of HRS-2 in non-randomized trials. Similar improvements for renal function and survival have been found, although the latter would be expected given the natural history of the disease.

**Extracorporeal Therapies**

RRT continues to be the mainstay of supportive therapy for patients who, despite aggressive resuscitation, lose the function of all remaining nephrons. Effective RRT corrects metabolic disturbances, fluid overloaded states and problems with thermoregulation.

The molecular adsorbent recirculating system (MARS) is an innovative extracorporeal treatment that is thought to remove albumin-bound vasoactive substances such as NO, tumour necrosis factor, and other proinflammatory cytokines to help transiently recover hepatic function. It has been used in patients with HRS-1 and resulted in clinical improvement in renal function producing a positive effect on 30-day survival in these patients (37.5 vs. 0%). This study was small, and they did not receive albumin or terlipressin therapy [41]. Future studies with MARS, vasoactive therapies and albumin will be necessary to evaluate its role further.

**Critical Care Issues**

The Liver Intensive Care Unit at King’s College Hospital is a specialist 15-bed unit dedicated to the admission and management of patients with liver disease. The patient population consists of both medical and surgical patients with liver disease. The medical patients consist of those who have become critically ill with decompensated cirrhosis or various presentations of acute liver failure. The surgical patients are a mix of those: post-liver transplant, small for size syndromes, liver trauma or following the resection of both primary and secondary hepatic tumours.

**Systematic Issues**

**Airway**

Encephalopathy in these patients demands protection of the airway. Intubation with an endotracheal tube initially, and at an appropriate and safe time tracheostomy is performed. Rapid sequence intubation is used in patients with ascites, as delayed gastric emptying from increased abdominal pressures increases the risk of aspiration. Tracheostomy allows the reduction of sedation necessary for patients to tolerate the endotracheal tube, which would otherwise delay recovery in these already encephalopathic patients.
Cardiovascular

Adequate organ perfusion is maintained by the early use of haemodynamic monitoring to optimize volume resuscitation along with vasopressor use. Steroids are used to help up-regulate adrenoreceptors, and when vasopressor use is significant or prolonged the hypothalamic-pituitary-adrenocortical axis is often assessed using the Synacthen test, despite the known pitfalls. Intra-abdominal pressure (IAP) is monitored using bladder manometers, and paracentesis performed whenever there are resultant circulatory or respiratory issues.

Respiratory

In critically ill cirrhotic patients there is a wide spectrum of respiratory problems encountered. Ventilator-associated pneumonia occurs despite ventilator care bundles being rigorously implemented. Adult respiratory distress syndrome, hydrothoraces and the hepatopulmonary syndromes are also encountered.

Gastrointestinal

Gut failure and the associated issues of poor absorption of enteral feeds require early placement of nasojejunal tubes and use of total parenteral nutrition. Supplementation with vitamins and trace element are used because of the increased requirement during critical illness with liver disease and use of continuous renal replacement therapies.

Conclusions

(1) Renal dysfunction is associated with an increased mortality in patients with cirrhosis. (2) There is a probably higher incidence of CKD – type 2 HRS. (3) Type 1 HRS is similar to that of AKI in sepsis/systemic inflammatory response syndrome with treatment aimed at early central volume expansion. (4) Problems with the definition of HRS make it difficult to use in clinical practice, recent attempts to stage both AKI and CKD provide potential alternatives to the threshold SCr concentrations currently used. (5) Evidence base for terlipressin and albumin appears to be good. (6) Accurate biomarkers of kidney injury are needed to help diagnose injury to the kidney earlier. (7) TIPSS may be considered in selected patients (CP score <12 and early responders to medical therapy). (8) Transplantation is an option, but a high incidence of renal dysfunction in recipients due to immunosuppression and diabetes is often observed.

References


